Moleculin Biotech, Inc. (NASDAQ:MBRX) Shares Shorted: Short Interest Down 38.3% in October

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the recipient of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totaling 126,324 shares, a decrease of 38.3% from the September 30th total of 204,583 shares. Based on an average daily volume of 354,271 shares, the short-interest ratio is presently 0.4 days. Currently, 15.0% of the company’s stock are sold short.

Moleculin Biotech Price Performance

Shares of MBRX opened at $7.90 on Friday. The firm has a 50-day moving average of $10.84 and a 200-day moving average of $40.73. Moleculin Biotech has a one year low of $3.23 and a one year high of $315.00. The company has a market cap of $8.14 million, a PE ratio of -1.11 and a beta of 2.00.

Moleculin Biotech (NASDAQ:MBRX) last issued its earnings results on Thursday, August 13th. The company reported ($28.00) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($31.00) by $3.00. Analysts expect that Moleculin Biotech will post -47.40 earnings per share for the current year.

Wall Street Analyst Weigh In

MBRX has been the subject of a number of analyst reports. Wall Street Zen upgraded Moleculin Biotech from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Thursday, October 15th. Finally, HC Wainwright dropped their price objective on Moleculin Biotech to $60.00 and set a “buy” rating on the stock in a research note on Friday, August 28th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $60.00.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on developing treatments for cancers and other serious diseases. The company uses its proprietary technology platforms to design drug candidates intended to address treatment resistance, improve drug delivery, and target biological pathways involved in disease progression.

Moleculin’s lead program is Annamycin, a liposomal formulation of the anthracycline doxorubicin being investigated for acute myeloid leukemia and soft-tissue sarcoma.